While the anti-VEGFR monoclonal antibody bevacizumab is used for patients with RAS mutant advanced CRC, cetuximab and panitumumab, two anti-EGFR monoclonal antibodies, are approved for individuals with RAS wild-type disease11,44 (Fig. 1). Here, EGFR is linked to colorectal carcinoma.